Efficacy and limitations of ribociclib (ribociclib) in breast cancer

Ribociclib (Ribociclib), an innovative drug targeting hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer, has attracted much attention in recent years. As an inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), it can effectively inhibit the growth and division of cancer cells. However, the answer to the question of whether it can completely eliminate tumors is not absolute.

Ribociclib interferes with the functions of CDK4 and CDK6, thereby interrupting the progression of cells from the G1 phase into the S phase, thereby achieving the purpose of slowing down the proliferation of cancer cells. When ribociclib (ribociclib) was combined with an aromatase inhibitor, the amount of time patients lived without worsening was significantly improved.

However, it is important to note that ribociclib does not guarantee complete disappearance of tumors in all patients. The effectiveness of treatment is affected by multiple factors such as the patient's personal situation, tumor characteristics, treatment plan adopted, and individual response to drugs. In some patients, ribociclib can significantly shrink tumors and effectively delay the disease. But it is also possible that the tumor can only be controlled but not completely eliminated.

In order to improve the therapeutic effect, Ribociclib (Riboxiclib) is often used in combination with drugs such as aromatase inhibitors or fulvestrant in order to achieve a stronger anti-cancer effect. However, to achieve complete disappearance of tumors, the comprehensive use of multiple treatments such as surgery, radiotherapy, and chemotherapy is often required.

To sum up, Ribociclib (Riboxiclib) has indeed shown a significant effect in the treatment of breast cancer, but whether it can completely eliminate tumors still needs to be comprehensively judged based on the patient's specific situation and treatment plan.